ArticleThe European respiratory journal2018
ACE2 as therapy for pulmonary arterial hypertension: the good outweighs the bad.
Article in The European respiratory journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04331470 (Evaluation of Efficacy of Pharmacotherapy Treatment of COVID- 19 Infection Using Oral Levamisole and Formoterol+Budesonide Inhaler and Comparison of This Treatment Protocol With Standard National Treatment of the Disease), which is not on this map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Efficacy of Pharmacotherapy Treatment of COVID- 19 Infection Using Oral Levamisole and Formoterol+Budesonide Inhaler and Comparison of This Treatment Protocol With Standard National Treatment of the Disease
Who cites it
26 citing papers in PubMed.
- Fenofibrate as a Modulator of the Renin-Angiotensin System in Su/Hx-Induced Pulmonary Arterial Hypertension.International journal of molecular sciences · 2025Article
- Effect of Pituitary-Target Gland Axis on RAAS in the Context of COVID-19.International journal of medical sciences · 2025Review
- Recombinant ACE2 - Opportunities and Challenges in COVID-19 Treatment.Infectious disorders drug targets · 2025Review
- Role of local angiotensin II signaling in bladder function.American journal of physiology. Renal physiology · 2024Review
- Exposure to a mixture of per-and polyfluoroalkyl substances modulates pulmonary expression of ACE2 and circulating hormones and cytokines.Toxicology and applied pharmacology · 2022Article
- An update on angiotensin-converting enzyme 2 structure/functions, polymorphism, and duplicitous nature in the pathophysiology of coronavirus disease 2019: Implications for vascular and coagulation disease associated with severe acute respiratory syndrome coronavirus infection.Frontiers in microbiology · 2022Review
- Phytoconstituents from ten natural herbs as potent inhibitors of main protease enzyme of SARS-COV-2:Phytomedicine plus : international journal of phytotherapy and phytopharmacology · 2021Article
- Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial.EClinicalMedicine · 2021Article
- Renin Angiotensin Aldosterone System Antagonism in 2019 Novel Coronavirus Acute Lung Injury.Open forum infectious diseases · 2021Review
- Review
- Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2.Communications biology · 2021Article
- Angiotensin-Converting Enzyme 2 Activator Ameliorates Severe Pulmonary Hypertension in a Rat Model of Left Pneumonectomy Combined With VEGF Inhibition.Frontiers in medicine · 2021Article
- Molecular Mechanisms of Proteins - Targets for SARS-CoV-2 (Review).Sovremennye tekhnologii v meditsine · 2021Review
- Interplay of COVID-19 and cardiovascular diseases in Africa: an observational snapshot.Clinical research in cardiology : official journal of the German Cardiac Society · 2020Review
- Pulmonary Artery Thrombosis: A Diagnosis That Strives for Its Independence.International journal of molecular sciences · 2020Review
- Cancer Patients Have a Higher Risk Regarding COVID-19 - and Vice Versa?Pharmaceuticals (Basel, Switzerland) · 2020Article
- COVID-19 pandemic and therapy with ibuprofen or renin-angiotensin system blockers: no need for interruptions or changes in ongoing chronic treatments.Naunyn-Schmiedeberg's archives of pharmacology · 2020Review
- Is targeting Akt a viable option to treat advanced-stage COVID-19 patients?American journal of physiology. Lung cellular and molecular physiology · 2020Review
- The liaison between respiratory failure and high blood pressure: evidence from COVID-19 patients.The European respiratory journal · 2020Observational
- Stages or phenotypes? A critical look at COVID-19 pathophysiology.Intensive care medicine · 2020Article
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
29929959What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.